Covera Health Acquires Medmo to Build End-to-End Radiology Platform

Covera Health, a diagnostic quality verification platform backed by Insight Partners, has acquired Medmo, an imaging appointment scheduling and marketplace company. Terms weren't disclosed, but the deal creates what both companies claim is the first platform to manage the entire radiology workflow — from the moment a doctor orders a scan to the final diagnostic interpretation.

The combination isn't just about workflow efficiency. It's about closing a diagnostic accuracy gap that affects roughly 500 million imaging scans performed annually in the U.S. — scans that range from routine X-rays to complex MRIs, many of which are interpreted by radiologists working outside their subspecialty or in facilities without quality oversight infrastructure.

Covera's platform analyzes radiologist performance data to identify which providers deliver the most accurate reads for specific conditions. Medmo's technology connects patients with imaging centers and manages appointment logistics. Together, they're betting that controlling both ends of the process — where patients get scanned and who reads those scans — will reduce misdiagnosis rates that cost the U.S. healthcare system an estimated $100 billion annually in unnecessary treatments, repeat imaging, and delayed care.

"We're solving the last-mile problem in diagnostic accuracy," said Ron Vianu, CEO of Covera Health, in the announcement. "You can have the best imaging equipment in the world, but if the wrong radiologist reads your scan — or reads it outside their expertise — the outcome suffers. Now we can optimize both sides."

Here's the problem Covera and Medmo are addressing: most patients and referring physicians have no visibility into radiologist quality when an imaging study is ordered. A patient books an MRI through their insurance network or hospital referral. The scan happens. A radiologist — often selected based on availability, not subspecialty match — reads it. The report goes back to the ordering doctor.

But radiology isn't a commodity. A musculoskeletal specialist reading a cardiac MRI, or a general radiologist interpreting a complex oncology scan, introduces material diagnostic risk. Studies show diagnostic error rates in radiology range from 3-5% for routine cases to over 30% in subspecialty areas when non-expert readers are involved.

Covera built its business on making that invisible risk visible. The company's platform ingests claims data, clinical outcomes, and peer review results to score radiologists on accuracy by subspecialty and scan type. Health plans and provider networks use those scores to route scans to high-performers, particularly for complex or high-stakes cases like cancer staging or stroke evaluation.

The company works with major health plans including Humana, Florida Blue, and Tufts Health Plan, covering over 50 million members. But until now, Covera's influence began after the scan was already scheduled and performed — missing the upstream opportunity to direct patients toward facilities whose radiologists score well in Covera's quality metrics.

That's where Medmo comes in. Founded in 2016, the company built a consumer-facing marketplace and enterprise scheduling platform for medical imaging. Patients and providers use Medmo to compare prices, check availability, and book appointments across a network of over 5,000 imaging facilities in the U.S. The platform handles insurance verification, pre-authorization, and price transparency — pain points that traditionally add days or weeks to the scheduling process.

Medmo's typical user is either a self-directed patient searching for lower-cost imaging options or a physician's office that needs to get a patient scheduled quickly without phone tag. The company also partners with health systems and employers to offer imaging concierge services, where a care coordinator handles the entire booking process.

The business model is transactional: Medmo takes a fee per booked appointment, typically paid by the imaging facility or the payer. The company raised $6.1 million in venture funding across two rounds, most recently a $3.5 million Series A in 2018, and scaled without raising significant additional capital — a signal that the business reached operational sustainability but lacked the resources to attack a much larger market opportunity.

Now, under Covera's ownership, Medmo's scheduling engine becomes the steering mechanism for Covera's quality network. When a patient books through the combined platform, the system can route them not just to an available or affordable facility, but to one whose radiologists have demonstrably higher accuracy for that specific scan type.

The integrated product works like this:

The entire loop closes in Covera's data infrastructure, which continuously updates radiologist performance metrics based on downstream outcomes — whether a diagnosis was confirmed by biopsy, whether a patient required additional imaging, whether treatment followed evidence-based protocols.

Covera's acquisition of Medmo is the latest in a wave of vertical integration moves in healthcare software, where companies that previously owned a single layer of the value chain are expanding upstream or downstream to capture more margin and control more of the patient experience. Teladoc's acquisition of Livongo, Optum's rollup of physician practices, and One Medical's combination with Amazon all follow this pattern — own more of the care continuum to reduce leakage and improve outcomes.

For Covera, the timing reflects market readiness. Five years ago, directing patients to specific radiologists based on quality scores would've been met with resistance from health systems and radiologists themselves. But rising pressure on diagnostic accuracy — driven by value-based care contracts, malpractice concerns, and regulatory scrutiny — has shifted the conversation.

Health plans now have financial incentives to reduce diagnostic errors. Under risk-bearing contracts, a missed cancer diagnosis or delayed stroke identification directly impacts their bottom line. Covera's pitch is straightforward: pay us to route scans to better radiologists, and we'll reduce your downstream costs from avoidable errors.

The addressable market is substantial. According to the announcement, the combined company targets a $3 billion opportunity across imaging scheduling, quality assurance, and second opinion services. That figure assumes penetration into both the commercial insurance market — where patients have choice in where they get scanned — and the Medicare Advantage segment, where plans are increasingly experimenting with narrow networks and steerage programs.

Medmo's existing footprint accelerates Covera's go-to-market. Rather than building scheduling infrastructure from scratch, Covera inherits a platform already integrated with thousands of facilities and processing tens of thousands of appointments annually. The operational lift is in aligning Medmo's facility network with Covera's quality scoring — a data engineering challenge, but one with clear ROI if it reduces misdiagnosis rates even marginally.

The combined platform faces three structural challenges.

First, radiologist resistance. Covera's quality scoring is inherently comparative — some radiologists will rank higher, others lower. Those on the wrong end of the distribution have every incentive to dispute the methodology, particularly if it affects their referral volume. Expect pushback from professional societies and individual practitioners who argue that Covera's metrics oversimplify a nuanced clinical process.

Second, data access. Covera's scoring depends on access to claims data, clinical outcomes, and peer review results — information that varies wildly in quality and availability across payers and geographies. In markets where data is sparse or siloed, the platform's quality differentiation collapses back to availability and price, exactly what Medmo already offered pre-acquisition.

Third, network effects are unproven. The platform's value proposition — better outcomes through quality routing — only works if patients and physicians consistently choose Covera's recommended facilities over alternatives. But patients prioritize convenience and cost. If Covera's top-rated facility is 20 miles farther or $200 more expensive, utilization will skew toward the closer, cheaper option, regardless of quality scores.

The company will need to prove, with longitudinal data, that its routing reduces downstream costs enough to justify any incremental friction or expense at the scheduling stage. That's a multi-year evidence-building exercise, and health plans don't typically wait years to evaluate vendor performance.

Covera isn't the only company trying to insert itself into the radiology value chain. Several competitors are attacking adjacent parts of the problem:

Viz.ai and Aidoc use AI to triage critical findings — like strokes or pulmonary embolisms — and alert radiologists and care teams in real time. That's a different play than Covera's quality routing, but it addresses the same underlying concern: diagnostic delays kill patients.

Covera Health is a portfolio company of Insight Partners, the growth-stage software investor with $90 billion in assets under management. Insight led Covera's Series B in 2021 and has been the company's primary institutional backer since. The Medmo acquisition is almost certainly Insight-funded, though neither company disclosed deal terms.

Insight's thesis here is straightforward: healthcare software companies that control demand and supply simultaneously — patient flow and provider networks — command higher valuations and more defensible market positions than point solutions. Medmo gives Covera demand-side control (where patients book). Covera's quality network gives it supply-side differentiation (which radiologists get the volume).

The combined entity fits Insight's portfolio strategy of backing vertical software platforms in large, fragmented markets. Radiology is a $12 billion market in the U.S. alone, characterized by independent imaging centers, hospital-based radiology groups, and teleradiology providers, none of which dominate. If Covera can aggregate demand through Medmo's scheduling layer and route it to a curated quality network, it inserts itself as the intermediary that captures value from both sides.

The exit path likely involves either a strategic acquisition by a major health plan, a radiology services company like RadNet or Alliance HealthCare Services, or continued growth toward an eventual public offering. Insight's typical hold period is 5-7 years, which suggests Covera is being positioned for a liquidity event in the 2026-2028 window.

For health systems, the Covera-Medmo combination is both an opportunity and a threat.

Opportunity: Health systems that participate in Covera's quality network and score well on subspecialty accuracy can gain referral volume from health plans and self-directed patients using the platform. This is particularly valuable for academic medical centers and specialty hospitals that want to attract complex cases but struggle to differentiate on quality in a commoditized imaging market.

Threat: Health systems that lose patients to Covera-preferred competitors face margin pressure. Imaging is a high-margin service line for most hospitals. If a health plan or employer directs patients away from a system's imaging centers — even when those centers are in-network — the system loses revenue without a corresponding reduction in fixed costs.

Referring physicians, meanwhile, face workflow changes. If Covera's platform becomes embedded in health plan referral systems or EMR workflows, physicians may lose discretion over where they send patients for imaging. That's a double-edged sword: it reduces administrative burden (no more hunting for appointment availability), but it also removes clinical judgment from facility selection.

Covera's long-term product roadmap, accelerated by the Medmo acquisition, extends beyond first-read quality into second opinions and AI-augmented interpretation. The company already offers a second opinion service for complex cases, where a subspecialty radiologist reviews an initial read and flags discrepancies. With Medmo's patient-facing interface, Covera can now offer that service directly to consumers, not just through health plan contracts.

The second opinion market is undersized relative to the problem it addresses. Studies estimate 10-20% of radiology reports contain clinically significant errors, but fewer than 2% of patients seek second opinions, mostly because they don't know it's an option or can't navigate the logistics. Medmo's scheduling layer and Covera's radiologist network remove those barriers.

AI integration is the other frontier. Covera has signaled interest in overlaying AI-driven quality assurance tools that flag outlier reads or suggest alternative diagnoses based on pattern recognition across millions of scans. The company isn't building its own AI models — it's more likely to partner with or acquire existing AI radiology companies — but the combined platform creates a natural distribution channel for those tools.

If Covera can package quality routing, second opinions, and AI-driven safety nets into a single integrated offering, it moves from a diagnostic services company to a patient safety infrastructure company — a much larger and more defensible market position.

The Covera-Medmo deal is a bet that the radiology market is ready for quality-based steerage. Whether that bet pays off depends on three things:

First, data. Covera needs consistent access to high-quality outcomes data across geographies and payers. Without it, the platform's differentiation collapses.

Second, adoption. Health plans, employers, and patients need to trust Covera's quality scores enough to override convenience and cost preferences. That requires not just good data, but effective storytelling and demonstrated impact.

Third, radiologist buy-in. If the radiology community treats Covera as a threat rather than a partner, the company will face professional and political headwinds that slow adoption regardless of clinical evidence.

The next 18 months will reveal whether the combined company can convert its expanded product footprint into measurable improvements in diagnostic accuracy — and whether payers and patients care enough about quality to change their behavior. If they do, Covera has a shot at redefining how diagnostic services are bought and sold. If they don't, this becomes another vertical integration play that looked better on paper than in practice.